National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting, 76744 [2011-31551]

Download as PDF 76744 Federal Register / Vol. 76, No. 236 / Thursday, December 8, 2011 / Notices Developmental Status: Proof of concept and pre-clinical development ongoing. • Anti-Tumor Immunity Elicited by Defensin Tumor Antigen Fusion Proteins (E–196–2000). Patent Status: US Patent No. 7,754,676 issued 13 Jul 2010; US Patent No. 7,915,040 issued 29 Mar 2011; US Patent Application No. 13/019,160 filed 01 Feb 2011. Developmental Status: Clinical Trials Pending. • Vaccine for the Treatment of Malignancies Expressing Immature Laminin Receptor Protein (OFA–iLRP) (E–271–2006). Patent Status: US Patent Application No. 11/899,165 filed 03 Sep 2007; US Provisional Application No. 60/841,927 filed 01 Sep 2006. Developmental Status: Pre-clinical with ongoing clinical tests in patients with NSCLC. • Tumor Associated Antigen SPANX– B for Cancer Immunotherapy (E–089– 2009). Patent Status: US Provisional Application No. 61/156,435 filed 27 Feb 2009. Developmental Status: Ongoing In vitro pre-clinical studies on human tumor cells. References mstockstill on DSK4VPTVN1PROD with NOTICES 1. A Biragyn et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol. 1999 Mar;17(3):253–258. [PMID 10096292] 2. A Biragyn et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol. 2001 Dec 1;167(11):6644– 6653. [PMID 11714836] 3. G Almanzar et al. Sperm-derived SPANX– B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells. Clin Cancer Res. 2009 Mar 15;15(6):1954–1963. [PMID 19276289] For information on the Immunotherapeutics Unit, Laboratory of Molecular Biology and Immunology of the National Institute on Aging (NIA), please visit: https://www.grc.nia.nih.gov/ branches/lmbi/cis_itu.htm. Dated: December 2, 2011. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2011–31554 Filed 12–7–11; 8:45 am] BILLING CODE 4140–01–P VerDate Mar<15>2010 15:59 Dec 07, 2011 Jkt 226001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel. Date: January 30–31, 2012. Time: 6 p.m. to 7 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance Washington, DC Dupont Circle Hotel, 1143 New Hampshire Avenue, NW., Washington, DC 20037. Contact Person: Manana Sukhareva, PhD, Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Boulevard, Suite 959, Bethesda, MD 20892, (301) 451–3397, sukharem@mail.nih.gov. Dated: December 2, 2011. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–31551 Filed 12–7–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Use of Agents Targeting Thrombospondin-1 and CD47 To Treat Radiation-Induced Damage and Enhance the Effectiveness of Radiotherapy in Cancer Patients National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is a notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR SUMMARY: PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive license, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/850,132, filed October 6, 2006, now abandoned (HHS Ref. No. E–227–2006/0–US–01); U.S. Provisional Patent Application No. 60/ 864,153, filed November 02, 2006, now abandoned (HHS Ref. No. E–227–2006/ 1–US–01); U.S. Provisional Patent Application No. 60/888,754, filed February 07, 2007, now abandoned (HHS Ref. No. E–227–2006/2–US–01); U.S. Provisional Patent Application No. 60/910,549, filed April 06, 2007, now abandoned (HHS Ref. No. E–227–2006/ 3–US–01); U.S. Provisional Patent Application No. 60/956,375, filed August 16, 2007, now abandoned (HHS Ref. No. E–227–2006/4–US–01); PCT Patent Application No. PCT/2007/ 080647, filed October 5, 2007, now abandoned (HHS Ref. No. E–227–2006/ 5–PCT–01); U.S. Patent Application No. 12/444,364, filed April 3, 2009 (HHS Ref. No. E–227–2006/5–US–02); Canadian Patent Application No. 2,665,287, filed October 5, 2007 (HHS Ref. No. E–227–2006/5–CA–03); Australian Patent Application No. 2007319576, filed October 5, 2007 (HHS Ref. No. E–227–2006/5–AU–04); European Patent Application No. 07868382.8, filed October 5, 2007 (HHS Ref. No. E–227–2006/5–EP–05); U.S. Provisional Patent Application No. 61/ 086,991, filed August 7, 2008, now abandoned (HHS Ref. No. E–153–2008/ 0–US–01); PCT Patent Application No. PCT/2009/052902, filed August 5, 2009, now abandoned (HHS Ref. No. E–153– 2008/0–PCT–02); U.S. Patent Application No. 13/057,447, filed February 3, 2011 (HHS Ref. No. E–153– 2008/0–US–06); Canadian Patent Application No. 2732102 filed August 5, 2009 (HHS Ref. No. E–153–2008/0–CA– 043); Australian Patent Application No. 2009279676, filed August 5, 2009 (HHS Ref. No. E–153–2008/0–AU–03); and European Patent Application No. 09791202.6, filed August 5, 2009 (HHS Ref. No. E–153–2008/0–EP–08), entitled ‘‘Prevention of Tissue Ischemia, Related Methods and Compositions,’’ and ‘‘Radioprotectants Targeting Thrombospondin-1 and CD47,’’ to Radiation Control Technologies, Inc., a company incorporated under the laws of the State of Delaware having its headquarters in Rockville, Maryland. The United States of America is the assignee of the rights of the above inventions. The prospective exclusive license territory may be ‘‘worldwide,’’ E:\FR\FM\08DEN1.SGM 08DEN1

Agencies

[Federal Register Volume 76, Number 236 (Thursday, December 8, 2011)]
[Notices]
[Page 76744]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31551]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Biomedical Imaging and Bioengineering; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.
    Name of Committee: National Institute of Biomedical Imaging and 
Bioengineering Special Emphasis Panel.
    Date: January 30-31, 2012.
    Time: 6 p.m. to 7 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Renaissance Washington, DC Dupont Circle Hotel, 1143 New 
Hampshire Avenue, NW., Washington, DC 20037.
    Contact Person: Manana Sukhareva, PhD, Scientific Review Officer, 
National Institute of Biomedical Imaging and Bioengineering, National 
Institutes of Health, 6707 Democracy Boulevard, Suite 959, Bethesda, MD 
20892, (301) 451-3397, sukharem@mail.nih.gov.

    Dated: December 2, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-31551 Filed 12-7-11; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.